Oligonucleotide
Nedosiran
Own facility · Oligonucleotide
Nedosiran is a GalNAc-conjugated siRNA targeting hepatic lactate dehydrogenase A (LDHA), developed to reduce oxalate production in primary hyperoxaluria.
Supply offerings
| Business line | Business model | Regulatory status |
|---|---|---|
| APIOligonucleotide | Own facility supply | n/a |
Supplied for pharmaceutical manufacturing and R&D by licensed and qualified entities. Not for human use as supplied. Availability is subject to regulatory approval in the buyer's jurisdiction.